Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Myotonic dystrophy type 2.

¹Neurologisches Krankenhaus Rosenhügel, Vienna, Austria. josef.finsterer@nkr.magwien.gv.at

European Journal of Neurology

|September 11, 2002

Summary

This summary is machine-generated.

Myotonic dystrophy type 2 (DM2) is a multisystem disorder clinically similar to DM1. Diagnosis relies on DNA analysis due to overlapping symptoms and genetic heterogeneity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nonspecific lower back pain in overhead athletes is multifactorial and is not solely determined by the type and intensity of the sport.

South African journal of sports medicine·2026

Same author

The spectrum of developmental and epileptic encephalopathies and their genetic heterogeneity are much broader than previously thought.

The Medical journal of Malaysia·2026

Same author

Bilateral hack sign not necessarily implies paraparesis.

Neurologia·2025

Same author

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios can only predict the severity of COVID-19 if the criteria for a biomarker are met.

The Medical journal of Malaysia·2025

Same author

The spectrum of ophthalmologic abnormalities in MELAS is broader than expected.

Archivos de la Sociedad Espanola de Oftalmologia·2025

Same author

In Patients not Suitable for Generalised Anaesthesia, Surgery for Necrotising Fasciitis under Spinal Anaesthesia should be Considered.

Malaysian orthopaedic journal·2025

Same journal

Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study.

European journal of neurology·2026

Same journal

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?

European journal of neurology·2026

Same journal

Direct Thrombectomy vs. Combined Treatment With Intravenous Thrombolysis in the Extended Time Window: A Target Trial Emulation.

European journal of neurology·2026

Same journal

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia-Telangiectasia: A Systematic Review.

European journal of neurology·2026

Same journal

Intensive Rehabilitation With Adjunctive Bilateral Anodal tDCS in Post-Stroke Dysphagia: A Multicenter Randomized Controlled Trial.

European journal of neurology·2026

Same journal

Distal Agrin (AGRN) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction.

European journal of neurology·2026

See all related articles

Area of Science:

Genetics
Neurology
Molecular Biology

Background:

Myotonic dystrophy type 2 (DM2) presents as a multisystem disorder with clinical similarities to myotonic dystrophy type 1 (DM1).
Historically, distinct phenotypes like proximal myotonic myopathy (PROMM) were described, sharing symptoms such as weakness, myotonia, and abnormalities in various organ systems.
The clinical distinctions between DM1 and DM2 phenotypes have become less clear over time.

Purpose of the Study:

To clarify the genetic basis and diagnostic criteria for myotonic dystrophy type 2 (DM2).
To consolidate understanding of DM2 despite its clinical heterogeneity.

Main Methods:

Genetic linkage studies mapped the mutated gene to chromosome 3q.
Identification of a specific mutation, a CCTG-repeat expansion in the ZNF9 gene, confirmed the genetic basis for DM2 phenotypes.

Related Experiment Videos

Main Results:

All previously described DM2 phenotypes (PROMM, DM2, PDM) were found to share the same mutation in the ZNF9 gene.
The causative mutation is a CCTG-repeat expansion (75-11,000 repeats) in intron 1 of the ZNF9 gene on chromosome 3q21.3.
Despite clinical heterogeneity, DM2 results from a single genetic mutation.

Conclusions:

Myotonic dystrophy type 2 (DM2) is genetically homogeneous, caused by a specific repeat expansion in the ZNF9 gene.
Due to overlapping clinical features, definitive diagnosis of DM2 requires DNA analysis.